Webinars & Videos

What are the top challenges in radiology for 2017?

At RBMA PaRADigm 2017 in Chicago, we asked numerous thought leaders from the imaging industry about the top challenges in radiology for 2017. This video includes many of those answers, which included radiation dose management, CDS implementation and more.

What is the word of the year in radiology for 2017?

At RBMA PaRADigm 2017 in Chicago, we asked numerous thought leaders from the imaging industry what the word of the year was in radiology for 2017. This video includes many different answers to that question, showing just how much is happening in the industry right now.

What is the biggest advance in cardiology in the last 10 years?

During the past 10 years, there have been major advancements in cardiology, according to physicians and healthcare leaders. Listen in to hear what cardiology leaders define as the most important.

What is the word of the year for healthcare in 2017?

Surreal was the Merriam Webster word of the year in 2016. Cardiovascular Business asks physicians and others involved in cardiology for their “word of the year” for 2017 is. We’ll give you a hint – the word of the year suggestions start with change and concern and emerge from there.
 

Why was palliative care featured at ACC.17?

Palliative care is a growing area in cardiovascular medicine, says ACC President Mary Norine Walsh, MD. Patients with heart failure and patients considering TAVR are among those who may benefit from working with the palliative care team. Listen in.

Teams benefit when all clinicians work to the top of their license

Teams benefit when providers work at the top of their license, according to Disty Pearson, PA-C. By doing so, it leads to mutual trust and respect. Instead of serving as the “quarterback” of the team, physicians may serve in more of a coaching role. 

SURTAVI: Take-aways for TAVR

Larry S. Dean, MD, provides insight on the randomized SURTAVI trial, which was presented in a late-breaking session at the ACC scientific session. At two years, intermediate-risk patients with severe symptomatic aortic stenosis had similar rates of all-cause mortality or disabling stroke whether they underwent TAVR or SAVR. Dean says the results confirm findings from the PARTNER IIA trial, which showed that TAVR can be effective in lower risk patients.